

For brokers and producers only

Date: June 10, 2021

Markets: All (Except FEP, Medicare Advantage and Medicare Supplemental)

2021 Rx Enhancements—Medical Pharmacy Management (MPM)

Effective **August 1, 2021**, the medications listed below covered under the medical benefit will require prior authorization and/or site of care to better manage rising specialty drug costs.

In addition, site of care drug criteria will expand to include patients 14-20 years old and older than 65 years old. This program enhancement supports CareFirst’s mission to drive members towards affordable and accessible care by steering utilization to lower-cost settings such as their home or their doctor’s office.

The medications added to MPM are new-to-market drugs, so there is no member impact for notification at this time. Providers will be notified in the June issue of BlueLink.

Prior authorization is required to ensure safe and effective use of these high-cost medications. Through prior authorization, site of care criteria is applied to selected medications as an opportunity to help reduce overall healthcare costs without compromising quality of care. The outpatient hospital setting is generally recognized as one of the most costly options for specialty infusions, with costs up to three times higher compared to non-hospital settings.

To view a full list of medications covered under the medical benefit that require prior authorization or subject to site of care, visit the [Specialty Drug List](#). This list is updated monthly.

Prior Authorization Additions

Drug Name	Drug Class	Drug Name	Drug Class
Abecma	Oncology	COSELA	Neutropenia
Amondys 45	Duchenne muscular dystrophy	RIABNI	Oncology

Failure to obtain prior authorization for these drugs may result in the denial of the claim payment.

Site of Care Additions

Drug Name	Drug Class
Oxlumo	Renal Disease

Coverage for these medications at an outpatient hospital setting is approved only if medical necessity criteria are met at the time of prior authorization. Members have the option to receive their infusion at an alternate site, including their home, an ambulatory infusion center or a physician's office.

For more information

If you have any questions, please contact your broker sales representative.